EA202091104A1 - Аденовирус и пути его применения - Google Patents
Аденовирус и пути его примененияInfo
- Publication number
- EA202091104A1 EA202091104A1 EA202091104A EA202091104A EA202091104A1 EA 202091104 A1 EA202091104 A1 EA 202091104A1 EA 202091104 A EA202091104 A EA 202091104A EA 202091104 A EA202091104 A EA 202091104A EA 202091104 A1 EA202091104 A1 EA 202091104A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- adenovirus
- ways
- application
- nucleic acid
- acid sequences
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10342—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение относится к последовательностям нуклеиновой кислоты аденовируса и аденовирусным векторам, содержащим указанные последовательности нуклеиновой кислоты. Аденовирусные векторы по изобретению можно использовать для индукции защитного иммунного ответа у субъекта.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17199347 | 2017-10-31 | ||
PCT/EP2018/079704 WO2019086450A1 (en) | 2017-10-31 | 2018-10-30 | Adenovirus and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091104A1 true EA202091104A1 (ru) | 2020-08-12 |
Family
ID=60413036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091104A EA202091104A1 (ru) | 2017-10-31 | 2018-10-30 | Аденовирус и пути его применения |
Country Status (13)
Country | Link |
---|---|
US (1) | US11872281B2 (ru) |
EP (1) | EP3703722B1 (ru) |
JP (1) | JP7438943B2 (ru) |
KR (1) | KR20200083510A (ru) |
CN (1) | CN111356466A (ru) |
AU (1) | AU2018359492B2 (ru) |
BR (1) | BR112020007698A2 (ru) |
CA (1) | CA3079210A1 (ru) |
EA (1) | EA202091104A1 (ru) |
IL (1) | IL274220A (ru) |
MX (1) | MX2020004492A (ru) |
SG (1) | SG11202003200VA (ru) |
WO (1) | WO2019086450A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
EP0784690B1 (en) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
EP0973866A4 (en) | 1997-03-04 | 2000-04-19 | Baxter Int | ADENOVIRUS E1-COMPLEMENTING CELL LINES |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
EP1200622A4 (en) | 1999-07-06 | 2004-12-22 | Merck & Co Inc | HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
EP1320621A4 (en) | 2000-09-15 | 2005-11-23 | Merck & Co Inc | ADVANCED FIRST-GENE ADENOVIRAL VACCINES EXPRESSING CODON OPTIMIZATION OF THE GAG, POL AND NEF PROTEINS OF HIV-1 AND CHANGES THEREOF |
EP1409012B1 (en) | 2001-06-22 | 2009-02-11 | The Wistar Institute Of Anatomy And Biology | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
NZ539509A (en) | 2002-10-23 | 2008-05-30 | Glaxosmithkline Biolog Sa | Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine |
ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
CN101883858B (zh) | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
CA2742474C (en) | 2008-11-03 | 2016-05-31 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
WO2010085984A1 (en) * | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
DK2536829T3 (en) | 2010-02-15 | 2016-07-04 | Crucell Holland Bv | A process for the production of Ad26-adenovirus vectors |
TR201902214T4 (tr) | 2010-04-16 | 2019-03-21 | Glaxosmithkline Biologicals Sa | Şempanze adenoviral vektörü-bazlı filovirüs aşıları. |
WO2013016591A1 (en) | 2011-07-26 | 2013-01-31 | Zuvachem, Inc. | High efficiency isoprene synthases produced by protein engineering |
EP2764011B1 (en) | 2011-10-05 | 2021-04-07 | GenVec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
SG10201609511XA (en) | 2012-05-18 | 2016-12-29 | Univ Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
-
2018
- 2018-10-30 KR KR1020207014973A patent/KR20200083510A/ko not_active Application Discontinuation
- 2018-10-30 MX MX2020004492A patent/MX2020004492A/es unknown
- 2018-10-30 EP EP18796011.7A patent/EP3703722B1/en active Active
- 2018-10-30 US US16/760,269 patent/US11872281B2/en active Active
- 2018-10-30 AU AU2018359492A patent/AU2018359492B2/en active Active
- 2018-10-30 EA EA202091104A patent/EA202091104A1/ru unknown
- 2018-10-30 CA CA3079210A patent/CA3079210A1/en active Pending
- 2018-10-30 SG SG11202003200VA patent/SG11202003200VA/en unknown
- 2018-10-30 JP JP2020524224A patent/JP7438943B2/ja active Active
- 2018-10-30 WO PCT/EP2018/079704 patent/WO2019086450A1/en unknown
- 2018-10-30 CN CN201880070184.5A patent/CN111356466A/zh active Pending
- 2018-10-30 BR BR112020007698-8A patent/BR112020007698A2/pt unknown
-
2020
- 2020-04-26 IL IL274220A patent/IL274220A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112020007698A2 (pt) | 2020-10-06 |
WO2019086450A1 (en) | 2019-05-09 |
IL274220A (en) | 2020-06-30 |
US20200323977A1 (en) | 2020-10-15 |
JP2021500911A (ja) | 2021-01-14 |
SG11202003200VA (en) | 2020-05-28 |
AU2018359492B2 (en) | 2023-12-14 |
KR20200083510A (ko) | 2020-07-08 |
CN111356466A (zh) | 2020-06-30 |
EP3703722B1 (en) | 2024-06-12 |
AU2018359492A1 (en) | 2020-04-16 |
EP3703722A1 (en) | 2020-09-09 |
US11872281B2 (en) | 2024-01-16 |
MX2020004492A (es) | 2020-11-24 |
CA3079210A1 (en) | 2019-05-09 |
JP7438943B2 (ja) | 2024-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091004A1 (ru) | Аденовирус и пути его применения | |
EA202091074A1 (ru) | Аденовирус и его применения | |
EA202091039A1 (ru) | Аденовирусные векторы и пути их применения | |
EA202091104A1 (ru) | Аденовирус и пути его применения | |
EA201890355A1 (ru) | Новые способы индукции иммунного ответа | |
IL263373A (en) | Genetically modified vaccinia virus, preparations containing it and its uses | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
CY1120671T1 (el) | Πολυπεπτιδιο πιρινης και ανοσοδιαμορφωση | |
EA201892386A1 (ru) | Химерные нейротоксины | |
EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
EA201890527A1 (ru) | Терапевтические вакцины против hpv18 | |
EA201791562A1 (ru) | Антигены цитомегаловируса и их применения | |
DK3280432T3 (da) | Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf | |
DK3310909T3 (da) | Sammensætninger og fremgangsmåder til at føre proteiner til specifikke loci i genomet | |
BR112017023975A2 (pt) | variantes de alfa-amilase e polinucleotídeos codificando as mesmas | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
MX2017007731A (es) | Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas. | |
TR201900274T4 (tr) | Geliştirilmiş adenovirüs formülasyonları. | |
EA201891460A1 (ru) | Композиция дендритных клеток | |
DK3465561T3 (da) | System til bufferlagring og sekvensering af laster omfattende to elevatorer | |
DK3649237T3 (da) | Nukleinsyre- og aminosyresekvenser fra ikke-humant menneskeabe-adenovirus, vektorer indeholdende samme og anvendelser deraf | |
EA201390866A1 (ru) | Филовирусные вакцины на основе аденовирусов серотипа 26 и серотипа 35 | |
PH12017501815A1 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
EA201692254A1 (ru) | Иммуномодулирующие прогениторные (имп) клетки | |
TN2019000109A1 (en) | Anti-c1s antibodies and methods of use thereof |